Sanofi pulls the plug on amlitelimab for eczema as it pivots its R&D
Sanofi is abandoning plans to seek approval for amlitelimab for atopic dermatitis after phase 3 results and safety data failed to show a meaningful improvement over current therapies; the decision follows leadership changes and a strategic review of the pipeline, though the company says no 2026 guidance will be changed and other indications remain under study.
